Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals

Giorgio Antonucci, Enrico Girardi, Alessandro Cozzi-Lepri, Maria Rosaria Capobianchi, Giulia Morsica, Paolo Pizzaferri, Nicoletta Ladisa, Laura Sighinolfi, Alessandro Chiodera, Mariacarmela Solmone, Eleonora Lalle, Giuseppe Ippolito, Antonella D'Arminio Monforte

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200 cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.

Original languageEnglish
Pages (from-to)109-117
Number of pages9
JournalAntiviral Therapy
Volume10
Issue number1
Publication statusPublished - 2005

Fingerprint

GB virus C
Highly Active Antiretroviral Therapy
Coinfection
HIV
RNA
CD4 Lymphocyte Count
Hepacivirus
Hepatitis C Antibodies
Viremia
RNA Viruses
Virus Diseases
Proportional Hazards Models
Observational Studies
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. / Antonucci, Giorgio; Girardi, Enrico; Cozzi-Lepri, Alessandro; Capobianchi, Maria Rosaria; Morsica, Giulia; Pizzaferri, Paolo; Ladisa, Nicoletta; Sighinolfi, Laura; Chiodera, Alessandro; Solmone, Mariacarmela; Lalle, Eleonora; Ippolito, Giuseppe; D'Arminio Monforte, Antonella.

In: Antiviral Therapy, Vol. 10, No. 1, 2005, p. 109-117.

Research output: Contribution to journalArticle

Antonucci, G, Girardi, E, Cozzi-Lepri, A, Capobianchi, MR, Morsica, G, Pizzaferri, P, Ladisa, N, Sighinolfi, L, Chiodera, A, Solmone, M, Lalle, E, Ippolito, G & D'Arminio Monforte, A 2005, 'Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals', Antiviral Therapy, vol. 10, no. 1, pp. 109-117.
Antonucci, Giorgio ; Girardi, Enrico ; Cozzi-Lepri, Alessandro ; Capobianchi, Maria Rosaria ; Morsica, Giulia ; Pizzaferri, Paolo ; Ladisa, Nicoletta ; Sighinolfi, Laura ; Chiodera, Alessandro ; Solmone, Mariacarmela ; Lalle, Eleonora ; Ippolito, Giuseppe ; D'Arminio Monforte, Antonella. / Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. In: Antiviral Therapy. 2005 ; Vol. 10, No. 1. pp. 109-117.
@article{b97c3bcf344c4c85aad87eb334665ebc,
title = "Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals",
abstract = "The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200 cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3{\%}) were GBV-C positive and, overall, 351 (87.8{\%}) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95{\%} CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.",
author = "Giorgio Antonucci and Enrico Girardi and Alessandro Cozzi-Lepri and Capobianchi, {Maria Rosaria} and Giulia Morsica and Paolo Pizzaferri and Nicoletta Ladisa and Laura Sighinolfi and Alessandro Chiodera and Mariacarmela Solmone and Eleonora Lalle and Giuseppe Ippolito and {D'Arminio Monforte}, Antonella",
year = "2005",
language = "English",
volume = "10",
pages = "109--117",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals

AU - Antonucci, Giorgio

AU - Girardi, Enrico

AU - Cozzi-Lepri, Alessandro

AU - Capobianchi, Maria Rosaria

AU - Morsica, Giulia

AU - Pizzaferri, Paolo

AU - Ladisa, Nicoletta

AU - Sighinolfi, Laura

AU - Chiodera, Alessandro

AU - Solmone, Mariacarmela

AU - Lalle, Eleonora

AU - Ippolito, Giuseppe

AU - D'Arminio Monforte, Antonella

PY - 2005

Y1 - 2005

N2 - The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200 cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.

AB - The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200 cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.

UR - http://www.scopus.com/inward/record.url?scp=18344393141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344393141&partnerID=8YFLogxK

M3 - Article

C2 - 15751768

AN - SCOPUS:18344393141

VL - 10

SP - 109

EP - 117

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -